Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the ngenla market grown in recent years?

In recent times, the ngenla market size has experienced a XX (HCAGR). Its growth projection indicates a surge from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. Factors such as the growing incidence of pediatric GHD, enhanced understanding of growth hormone deficiencies, increased global healthcare expenditure, escalating patient compliance issues, and authorization for novel treatments have contributed to this growth in the historical period.

How is the ngenla market size expected to evolve during the forecast period?

The size of the ngenla market is projected to experience an XX (FCAGR) over the forthcoming years, escalating to a value of $XX million in 2029 with a XX% Compound Annual Growth Rate. Several factors contribute to this expected growth within the forecasted timeframe, including the amplified demand for user-friendly treatment methods, a surge in the global pediatric population, increased investment in biologic research and development, the enlargement of health insurance coverage, along with a growing emphasis on personalized healthcare. Key trends within this period incorporate the emergence of progressive growth hormone therapies, market expansion into previously unexplored areas, the adoption of AI for patient monitoring, the rise of telemedicine for patients’ care, as well as a heightened regulatory focus towards patient safety.

Get your ngenla market report here!

https://www.thebusinessresearchcompany.com/report/ngenla-global-market-report

Which key drivers are propelling the ngenla market’s growth?

The steady rise in pediatric growth hormone deficiency (GHD) cases is anticipated to propel the ngenla market in the foreseeable future. Pediatric GHD is a disorder that is marked by insufficient development hormone secretion, subsequently affecting a child’s physical growth and overall well-being. Factors such as heightened awareness, advanced diagnostic resources, and greater accessibility to global health services are spurring the surge of GHD cases. Ngenla, an extended-release recombinant human growth hormone (somatrogon), addresses pediatric GHD by providing steady, routine release of growth hormone via injections once a week. This method mitigates the need for daily administration, boosts compliance, and effectively stimulates growth in children lacking adequate growth hormone. For instance, the National Library of Medicine (NLM), a US-based biomedical library, stated in January 2024 that GHD in children is not a common condition, with its prevalence ranging from 1 in 3,500 to 1 in 10,000, contingent on diagnostic criteria and stimulation test thresholds. Therefore, the escalating incidence of pediatric growth hormone deficiency (GHD) bolsters the ngenla market.

What are the market segments in the ngenla industry?

The ngenla market covered in this report is segmented –

1) By Indication: Growth Hormone Deficiency; Turner Syndrome; Prader-Willi; Small For Gestational Age

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By End User: Pediatric Patients; Adult Patients

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20259&type=smp

Which leading companies are shaping the growth of the ngenla market?

Major companies operating in the ngenla market are Pfizer Inc.

What key trends are currently impacting the ngenla market’s development?

The primary trend in the Ngenla market foregrounds progressions like long-acting growth hormone therapies, magnifying treatment adherence, and providing superior overall results for both pediatric and adult patients suffering from growth hormone deficiency. Long-lasting growth hormone treatments are crafted to maintain a consistent hormone emission, reducing the need for frequent injections thereby improving patient contentment in the treatment of such deficiencies. For example, Pfizer Inc., a biopharmaceutical firm in the US, with OPKO Health Inc., a US-based medicine firm, gained approval from the US Food and Drug Administration (FDA) for NGENLA (somatrogon-ghla), a human growth hormone analog that is administered once weekly, in June 2023. NGENLA is designated for the treatment of pediatric patients three years and older with growth failure due to inadequate endogenous growth hormone secretion.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20259

Which geographic areas are influencing the growth of the ngenla market?

North America was the largest region in the ngenla market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngenla market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Global Biosimilar Hormones Global Market Report 2025

https://thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Biosimilar Growth Hormones Global Market Report 2025

https://thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Parathyroid Hormone Global Market Report 2025

https://thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: